Cabozantinib (Cabometyx)

Ingredients: Cabozantinib
Dosage Form: Capsules
Innovator’s Brand Name: Cabometyx
Generic Brand Name: Caboxib
Generic Manufacturer: Ziska Pharma

Indications:
Cabozantinib is indicated for the treatment of advanced renal cell carcinoma and for hepatocellular carcinoma in patients previously treated with sorafenib.

Dosage and Administration:
The recommended dose is 60 mg orally once daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal). Discontinue at least 28 days prior to scheduled surgery. Dose adjustments may be necessary for patients with hepatic impairment or when coadministered with interacting medications.

Adverse Reactions:
Common adverse reactions include hemorrhage, gastrointestinal perforation or fistula formation, thromboembolic events, hypertension, diarrhea, palmar‑plantar erythrodysesthesia syndrome, proteinuria, osteonecrosis of the jaw, and impaired wound healing.

Storage:
Store in a cool, dry place below 30 °C, protected from light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link